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1. Needle and syringe sharing has declined in recent years, but 
almost one-fifth of injecting drug users continue to share. 
2. Infections are common among injecting drug users. Around 
one-half of injecting drug users have been infected with 
hepatitis C, one-sixth with hepatitis B, and about one-third 
reported a symptom of a bacterial infection (such as a sore 
or abscess) at an injecting site in the past year.
3. The prevalence of HIV among those who have injected drugs 
remains low and is estimated to be 1.5% overall in the UK.  
However, it varies across the country from 0.6% in Scotland 
to 4.1% in London.
4. The prevalence of HIV among current injectors has increased 
from 0.7% to 1.5% over the past decade, and is now similar 
to the level found in the early 1990’s. 
5. The uptake of HIV testing is improving, with three-quarters 
of injecting drug users now reporting that they have had a 
test; however, almost a third of injecting drug users with HIV 
remain unaware of their infection.
6. The vast majority of HIV-infected injecting drug users 
in contact with specialist HIV treatment services are receiving 
antiretroviral therapy.
Credits: Cover shutterstock
Health Protection Agency, Health Protection Scotland, Public Health Wales, CDSC 
Northern Ireland, and the CRDHB. Shooting Up: Infections among injecting drug users 
in the United Kingdom 2009. London: Health Protection Agency, November 2010.
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Injecting drug users (IDUs) are vulnerable to 
a wide range of viral and bacterial infections. 
These infections can result in high levels of 
illness and death, so public health surveillance 
of infectious diseases and associated risk, as well 
as of protective behaviours among this group 
are important. This report describes time trends 
on the extent of infections among IDUs in the 
UK, and is based on data to the end of 2009.  
This year’s report focuses on HIV infection.
HIV
Transmission of HIV through injecting drug use 
was recognised early in the HIV epidemic, when 
explosive outbreaks of HIV infection among 
IDUs occurred in many countries. 
HIV diagnoses
Between the beginning of the 1980s and the 
end of 2009 there had been a cumulative 
total of 5,272 HIV diagnoses reporteda in the 
UK where infection was thought to have been 
acquired through injecting drug use. These 
accounted for 5.0% of the cumulative total 
(106,252b) of HIV diagnoses in the UK, 3.9% 
(3,876/98,204) of those in England, 24% 
(1,324/5,621) in Scotlandc, 3.3% (56/1,701) in 
Wales and 2.3% (16/696) in Northern Ireland.  
The number of new HIV diagnoses among IDUs 
in recent years has been low and relatively 
stable, averaging 161 reports each year from 
2000 to 2009. So far, 149 new HIV diagnoses 
were reported in this group for 2009 (51 in 
London, 13 in Scotland and 85 elsewhere, 
Appendix Table 1). The proportion of HIV 
infections among IDUs newly diagnosed in 
the UK outside of London and Scotland, has 
increased from 39% (334/861) during 1995-
99 to 52% (469/902) during 2005-09. The 
probable country of infection was reported for 
66% (98) of new diagnoses in 2009. Where 
reported, 56% (55) of infections were probably 
acquired within the UK and 44% (43) outside the 
UK, mostly in Northern and Eastern Europe.
HIV-infected IDUs receiving care
The number of HIV-infected IDUs seen for HIV 
treatment and care in the UK has increased 
year-on-year during the past decade. In 2009, 
1,547 IDUs were seen for HIV treatment and 
care, an increase of 18% since 2000, when 
1,313 IDUs were seen. Whilst the total number 
of HIV-infected patients seen for care in 
Scotland increased between 2000 and 2009, 
the proportion infected through injecting drug 
use declined: 315 HIV-infected IDUs received 
care in 2009 compared to 419 in 2000. 
Across the UK, IDUs accounted for only 2.5% 
(1,547/62,194) of all HIV-infected adults 
(aged over 15 years) seen for care in the 
UK in 2009, having fallen gradually from 
6.0% in 2000 (1,313/21,730). In 2009, 71% 
(1,091/1,547) of HIV-infected IDUs were male 
and 88% (1,346/1,526) were white, and 79% 
(1,209/1,535) were receiving antiretroviral 
therapy, compared to 61% (738/1,210) in 2000. 
Of the IDUs seen for HIV-related care in 2009, 
around 37% (510/1,390) had CD4 counts of 
350 cells per mm3 or less - the level at which it 
is recommended to start antiretroviral therapy1. 
Equivalent figures were 20% (5,151/25,301) 
among men who have sex with men (MSM), 
and 30% (8,882/29,638) among heterosexuals. 
In 2009, of the 510 IDUs seen for care with 
CD4 counts of 350 or less, 90 (18%) were not 
on treatment; this is comparable to other risk 
groups (20% among MSM and 15% among 
heterosexuals).
a Based on reports received at the Centre for Infections by the end of June 2010.
b Includes 30 individuals were region of diagnosis is not known.
c The high overall proportion of IDUs among the diagnosed HIV infections in Scotland reflects individuals who were infected and diagnosed early in the epidemic. 
Since 2002 IDUs have accounted for around only one in twenty of new HIV diagnoses in Scotland.
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Figure 1: The prevalence of HIV infection among current and former injecting 
drug users: 2000 to 2009
Figure 2: The prevalence of HIV infection among recently† initiated injecting drug 
users in England, Wales & Northern Ireland*: 2000 to 2009
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* Data from Unlinked Anonymous Monitoring survey of injecting drug users in contact with specialist services. Includes Northern Ireland from 2002.
† Data for 2009 was not available at the time of publication.
† Those who started injecting drugs during the three years prior to participating in the survey.
* Includes Northern Ireland from 2002.
Data Source: Data from Unlinked Anonymous Monitoring survey of injecting drug users in contact with specialist services.
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HIV prevalence among IDUs
The overall HIV prevalence among IDUs in 2009 
was similar to that seen in recent years. Among 
those participating in the Unlinked Anonymous 
Monitoring (UAM) survey of current and former 
IDUs in England, Wales and Northern Ireland, 
the overall prevalence of antibodies to HIV was 
1.5% (49/3,289) in 2009 (Figure 1). In London, 
the prevalence was 4.1% (24/591, 95%CI 2.6%-
6.0%) while elsewhere in England it was 0.93% 
(22/2,371, 95%CI 0.58%-1.4%).  In Northern 
Ireland the prevalence was 1.3% (2/153, 95%CI 
0.16%-4.6%) and in Wales it was 0.57% (1/174, 
95%CI 0.01%-3.2%).
The UAM survey indicates that HIV transmission 
among IDUs might have increased in recent 
years. HIV prevalence among recent initiates 
(those who reported first injecting during the 
previous three years) is a measure of recent 
transmission. The prevalence among recent 
initiates participating in the UAM survey was 
0.71% (3/421) in 2009.  Prevalence in this 
group remains higher than it was prior to 2003 
(Figure 2); no HIV infections were detected in 
this group in 2000 (0/787)d.
In Scotland, the prevalence of HIV among IDUs 
is monitored through the surveillance of people 
undergoing voluntary confidential HIV testing. 
An HIV prevalence of 0.55% (13/2,381) among 
IDUs undergoing testing in Scotland was found 
during 2008. This compares with a prevalence 
of 1.4% to 3.2% in the early to mid-1990s and 
0.3% to 0.9% during the period 1998 to 2007 
(Figure 1). 
Current IDUs, those who have injected drugs 
in the past four weeks, are an important group 
because they will have been at recent risk of 
HIV infection. In 2009 the overall HIV prevalence 
among current IDUs taking part in the UAM 
survey in England, Wales & Northern Ireland was 
1.5% (28/1,874) - this is twice the level seen in 
this group in 2000 when prevalence was 0.72% 
(17/2,364)e (Figure 3). This increase has been 
focused outside London, where the prevalence 
was 0.20% (4/2,040) in 2000 and remained at 
around that level until 2003 (0.32%, 4/1,240). 
Subsequently, it increased to 0.63% (8/1,264) 
in 2004, and has remained elevated since then; 
it was 0.74% (12/1,627) in 2009f. In Scotland, 
633 IDUs (involving 452 current IDUs) were 
surveyed at settings that provided needle and 
syringe programmes (NSP) in three Health 
Boards during 2007. Only one respondent 
tested positive for HIV antibodies (0.16%, 
95%CI 0.004%-0.88%); none of the current 
IDUs tested positive.
HIV testing uptake among IDUs
Among IDUs, there has been an increase in the 
uptake of HIV testing in recent years. In 2009, 
25% of IDUs (782/3,126; 95%CI 24%-27%) who 
took part in the UAM survey reported never 
having had a voluntary confidential test for HIV. 
This is the lowest level ever recorded in this 
survey (Figure 4). Between 1990 (when the UAM 
survey started) and 2003, the uptake of HIV 
testing changed little, with 42% (1,126/2,651; 
95%CI 41%-44%) reporting never having had a 
test in 2002. 
Awareness of HIV infection in 2009 was 
comparable to previous years. Of the participants 
in the UAM survey who had antibodies to HIV, 
63% (27/43; 95%CI 47%-77%) were aware of 
their infection in 2009, which is similar to the 
levels seen in recent years (Figure 4). 
d After adjusting for age, gender, and if recruited in London or elsewhere in a multi-variable analysis the odds ratio for a one-year increase in time was 1.19 
(95%CI 1.05-1.36) indicating an annual increase of 19%.
e After adjusting for age, gender, and for region of recruitment in a multi-variable analysis the odds ratio for 2009 was 2.22 (95%CI 1.18-4.19) compared to 1.0 in 2000, 
indicating an over two-fold increase.
f After adjusting for age, gender, and for region of recruitment in a multi-variable analysis the odds ratio for 2009 was 3.97 (95%CI 1.26-12.5) compared to 1.0 in 2000, 
indicating a four-fold increase.
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Figure 3: The prevalence of HIV infection among current‡ injecting drug users in 
England, Wales & Northern Ireland*: 2000 to 2009
Figure 4: Uptake of voluntary confidential testing for HIV among current & former 
injectors and self-reported awareness of HIV positivity among current & former 
injectors with antibodies to HIV in England, Wales & Northern Ireland*: 2000 to 2009
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‡ Those who had last injected during the preceding four weeks.
* Includes Northern Ireland from 2002.
Data Source:  Data from Unlinked Anonymous Monitoring survey of injecting drug users in contact with specialist services.
* Includes Northern Ireland from 2002.
Data Source:  Data from Unlinked Anonymous Monitoring survey of injecting drug users in contact with specialist services.
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UPDATE ON OTHER INFECTIONS & 
BEHAVIOURS
Information on the extent of other infections and 
key behaviours among IDUs can be found in the 
three tables appended to this reportg. Key points 
are summarised below.
Hepatitis C: In 2009, 11,005 hepatitis C 
infections were diagnosed in the UK, and 
around 90% of these infections will have been 
acquired from injecting drug use (Table 1). UK 
wide data indicate that around half of IDUs are 
hepatitis C antibody positive: with 47% of the 
IDUs surveyed in England, Wales and Northern 
Ireland and 55% of those surveyed in Scotland 
having antibodies to hepatitis C (Table 1). 
Current levels of hepatitis C transmission among 
IDUs probably remain higher than a decade 
ago, as 24% of recent initiates participating 
in the UAM survey were infected in 2009 
compared with 12% in 2000 (Table 1).  Uptake 
of voluntary confidential testing for hepatitis C 
has increased among IDUs with the proportion 
reporting ever having been tested in England, 
Wales and Northern Ireland rising from 49% 
in 2000 to 81% in 2009.  Uptake of testing 
among those attending NSP in Scotland during 
2008-09 was 74% (Table 3). 
Hepatitis B: The transmission of hepatitis B 
continues among IDUs, but may have declined 
in recent years as the proportion of participants 
in the UAM survey ever infected has fallen 
from 28% in 2000 to 17% in 2009 (Table 1). In 
England, Wales and Northern Ireland reported 
uptake of the hepatitis B vaccine (i.e. accepting 
at least one dose) by IDUs has increased from 
35% in 2000 to 73% in 2009 (Table 3). Uptake 
of vaccination among those attending NSP in 
Scotland during 2008-09 was 68% (Table 3).
Bacterial infections: Injecting site infections 
remain common with 32% of IDUs 
participating in the UAM survey in 2009 
reporting an abscess, sore, or open wound 
at an injecting site during the preceding year 
(Table 2).  Illnesses associated with meticillin-
resistant Staphylococcus aureus and group A 
streptococcal infection are continuing to be 
reported among IDUs (Table 2).  There were 
also 22 cases of wound botulism and one case 
of tetanus reported in IDUs in 2009 (Table 2). 
In December 2009 there was the first reported 
case of anthrax among IDUs in the UK (see Box).
Risk Behaviours: The level of needle and 
syringe sharing reported in England, Wales 
and Northern Ireland has declined from 31% 
in 2000 to 19% in 2009 (Table 3).  In Scotland 
19% of IDUs reported needle and syringe 
sharing in 2008/09 (Table 3). 
Box: Anthrax Outbreak
Anthrax is a very rare infection caused by a bacterium that produces spores. These spores 
can survive in the environment for a long time and so can contaminate heroin during 
production or distribution. The first confirmed case of Anthrax among a drug user in the 
UK was reported in December 2009. Up to 30 September 2010 there had been a total of 
51 cases reported in the UK (47 in Scotland and four in England); of which 16 had died. 
During this period, two cases were also reported in Germany. There were no reports from 
elsewhere in Europe. In response to the cases, advice and information was issued to drug 
users and those who work with them2.
g Full data from the UAM survey can be found in the survey data tables at:  www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1202115519183
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CONCLUSIONS & RECOMMENDATIONS
Even though the level of injecting-related 
equipment sharing has declined in recent 
years, large numbers of IDUs continue to report 
injecting practices that put them at risk of 
acquiring infections. As a consequence, HIV, 
hepatitis B and C infections are continuing 
to occur among IDUs in the UK. The HIV 
prevalence among recent initiates to injecting 
suggests that HIV transmission among IDUs 
may be higher now than it was a decade 
ago.  Whilst combining data from across the 
UK suggests that about one in six IDUs have 
been infected with hepatitis B, and around 
half have been infected with hepatitis C. In 
addition, bacterial infections remain a problem 
among IDUs.  Interventions that aim to prevent 
infections among IDUs therefore need to be 
sustained and the levels of provision reviewed 
to ensure adequate coverage 3, 4, 5.
Those commissioning community-based 
services to reduce the harm associated with 
injecting drug use should give appropriate 
priority to preventing the spread of infections 
among IDUs and reducing the harm that these 
infections cause. Responses should be in line 
with national strategies 6, 7, 8, 9, 10, relevant action 
plans 11, 12, 13, 14, 15, related guidance 16, 17, 18, 19, 20, 21, 22, 
23, 24, 25 and local needs assessments 26, through 
the provision of:
1. Easy access to the following services 
through drug treatment services, general 
practitioners and needle and syringe 
programmes (NSP): 
a) Information and advice on safer injecting 
practices, avoiding injecting site 
infections, preventing blood-borne virus 
transmission and the safe disposal of 
used equipment. 
b) Hepatitis B vaccination and, as 
appropriate, tetanus and hepatitis A 
vaccination.
c) Diagnostic testing for HIV and hepatitis C, 
and care pathways for those infected.
d) Health checks and treatment for injection 
site infections.
e) Interventions to decrease or stop 
injecting and to support safer injection 
practice where it continues.
2. A range of easily accessible NSP for those 
unable to stop injecting (including those 
using drug treatment services). These 
programmes should distribute sufficient 
injecting-related equipment to prevent 
sharing and to support hygienic injecting 
practice as is appropriate. They should also 
offer interventions that support entry into 
drug treatment.
3. Drug treatment services that encourage 
drug users to reduce and cease injecting, 
and reduce or stop their drug use. 
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Indicator Area Sub-Category  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Hepatitis C infection              
Reported laboratory 
diagnoses of hepatitis C 
infection*
England 
Total number of reports: All exposures n 4,484 4,148 4,756 5,518 6,187 6,162 6,861 7,757 8,132 8,605*
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 91 95 96 95 96 96 95 98 99 97
Wales 
Total number of reports: All exposures n 300 256 284 262 184 274 311 286 167 207*
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 96 96 98 100 100 100 100 100 100 -
Scotland
Total number of reports: All exposures n 1,875 1,685 1,792 1,649 1,658 1,615 1,532 1,550 1,695 2,081
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 93 94 92 92 92 89 86 89 86 89
Northern 
Ireland
Total number of reports: All exposures n 54 65 75 86 100 134 135 114 132 112
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 82 75 89 86 100 93 100 100 88 -
Proportion hepatitis C 
antibody positive‡~
England, 
Wales & 
Northern 
Ireland^
Current & former injectors % 38 39 42 46 45 45 44 43 43 47
First injected during the preceding 3 years % 12 20 16 21 21 18 23 23 24 24
Prevalence among 
those having voluntary 
confidential HIV tests 
Glasgow
Injectors: All ages % 62 - 64 - - 67 72 63 -
Injectors: Age under 25 years % 41 - 42 - - 51 36 35 -
Proportion hepatitis C 
antibody positive§
Scotland
Current & former injectors % - - - - - - - - 55
Injectors with less than 3 years since onset 
of injecting
% - - - - - - - - 24
Hepatitis B infection              
Reported laboratory 
diagnoses of hepatitis B 
infection*
England†
Total number of reports: All exposures n 704 554 829 676 - - - - - -
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 46 37 37 38 - - - - - -
Wales†
Total number of reports: All exposures n 24 44 55 25 - - - - - -
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 35 39 69 27 - - - - - -
Scotland**
Total number of reports: All exposures n 360 357 354 342 341 372 375 475 615 775
Proportion of all reports indicating injecting 
drug use#
% 25 19 11 6.4 6.5 5.9 3.5 1.7 0.3 0.9
Northern 
Ireland***
Total number of reports: All exposures n 42 37 67 62 59 72 76 104 101 87
Proportion hepatitis B 
antibody positive‡~
England, 
Wales & 
Northern 
Ireland^
Current & former injectors % 28 28 29 30 28 26 28 20 18 17
First injected during the preceding 3 years % 9.3 11 9.1 12 8.9 9.4 14 6.3 3.1 7.1
HIV infection              
Reports of new 
diagnoses of HIV 
infection through 
injecting drug use*
London Total number of reports: Injecting drug use n 54 58 67 71 66 68 103 78 61 51
Scotland Total number of reports: Injecting drug use n 17 17 12 13 11 20 16 7 16 13
Rest of UK Total number of reports: Injecting drug use n 48 67 49 85 70 100 85 95 104 85
UK
Total number of reports: Men who have sex 
with men also reporting injecting drug use
n 32 20 27 22 16 20 14 13 11 14
Prevalence among 
those having voluntary 
confidential HIV tests 
Scotland All injectors tested % 0.7 0.7 0.5 0.6 0.5 0.9 0.7 0.3 0.5 ††
Proportion HIV antibody 
positive~
England, 
Wales & 
Northern 
Ireland^
Current & former injectors % 0.8 1.0 0.9 1.2 1.4 1.6 1.3 1.1 1.6 1.5
First injected during the preceding 3 years % 0 0.4 0.2 0.8 0.6 1.3 0.8 1.0 1.3 0.7
# Data on exposure is often incomplete or missing. 
* Numbers may be subject to revision due to reporting delay.
** Scottish data cannot reliably distinguish between acute and chronic hepatitis B infection.
*** Northern Ireland data prior to 2003 could not distinguish between acute and chronic 
hepatitis B infection: 2003 there were 12 acute cases, 20 in 2004, 20 in 2005, 17 in 2006, 
26 in 2007, 19 in 2008 and 26 in 2008.
† Publication of hepatitis B surveillance was stopped between 2004 and 2007 due to 
problems with the routine laboratory surveillance system. Cases of acute hepatitis B are now 
reported nationally from local health protection units (HPUs) and combined with laboratory 
data.  A total of 597 cases of acute hepatitis B were reported in England during 2009; 620 
cases were reported in 2008. Of the 398 acute and probable acute cases reported by HPUs 
in 2009, 226 (57%) had associated exposure information. The commonest reported risk 
factor for acute cases was heterosexual exposure, reported in 143 (63% of cases with known 
exposure). Injecting drug use was implicated in 30 (13%) cases.
^ Includes Northern Ireland from 2002.
~ Unlinked Anonymous Monitoring survey of injectors in contact with drug services:  
www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1202115519183
‡ Denotes past or current infection with hepatitis B/C.  Prior to 2009 this survey only 
collected oral fluid samples, however in 2009 both oral fluid and dried blood spot (DBS) 
samples were collected from participants. The sensitivities of the tests on DBS samples 
for antibodies to hepatitis C and hepatitis B core antigen are almost 100%.  However, the 
sensitivity of the Oral Fluid sample test for antibodies to hepatitis C is about 92% and that 
for antibodies to the hepatitis B core antigen is about 75%. Results presented are adjusted 
to allow for the poorer sensitivity of the tests on the Oral Fluids samples.
§Among individuals participating in a voluntary anonymous survey of injectors attending 
needle exchange services.
†† Data for 2009 was not available at the time of publication. 
‡ ‡ Data is for 1999-2000 .      
      
Table 1: Summary of indicators of viral hepatitis and HIV transmission among injecting drug users in the United Kingdom
Appendix
‡ ‡
‡ ‡
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Indicator Area Sub-Category  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Hepatitis C infection              
Reported laboratory 
diagnoses of hepatitis C 
infection*
England 
Total number of reports: All exposures n 4,484 4,148 4,756 5,518 6,187 6,162 6,861 7,757 8,132 8,605*
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 91 95 96 95 96 96 95 98 99 97
Wales 
Total number of reports: All exposures n 300 256 284 262 184 274 311 286 167 207*
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 96 96 98 100 100 100 100 100 100 -
Scotland
Total number of reports: All exposures n 1,875 1,685 1,792 1,649 1,658 1,615 1,532 1,550 1,695 2,081
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 93 94 92 92 92 89 86 89 86 89
Northern 
Ireland
Total number of reports: All exposures n 54 65 75 86 100 134 135 114 132 112
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 82 75 89 86 100 93 100 100 88 -
Proportion hepatitis C 
antibody positive‡~
England, 
Wales & 
Northern 
Ireland^
Current & former injectors % 38 39 42 46 45 45 44 43 43 47
First injected during the preceding 3 years % 12 20 16 21 21 18 23 23 24 24
Prevalence among 
those having voluntary 
confidential HIV tests 
Glasgow
Injectors: All ages % 62 - 64 - - 67 72 63 -
Injectors: Age under 25 years % 41 - 42 - - 51 36 35 -
Proportion hepatitis C 
antibody positive§
Scotland
Current & former injectors % - - - - - - - - 55
Injectors with less than 3 years since onset 
of injecting
% - - - - - - - - 24
Hepatitis B infection              
Reported laboratory 
diagnoses of hepatitis B 
infection*
England†
Total number of reports: All exposures n 704 554 829 676 - - - - - -
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 46 37 37 38 - - - - - -
Wales†
Total number of reports: All exposures n 24 44 55 25 - - - - - -
Proportion of all reports, with exposure data, 
indicating injecting drug use#
% 35 39 69 27 - - - - - -
Scotland**
Total number of reports: All exposures n 360 357 354 342 341 372 375 475 615 775
Proportion of all reports indicating injecting 
drug use#
% 25 19 11 6.4 6.5 5.9 3.5 1.7 0.3 0.9
Northern 
Ireland***
Total number of reports: All exposures n 42 37 67 62 59 72 76 104 101 87
Proportion hepatitis B 
antibody positive‡~
England, 
Wales & 
Northern 
Ireland^
Current & former injectors % 28 28 29 30 28 26 28 20 18 17
First injected during the preceding 3 years % 9.3 11 9.1 12 8.9 9.4 14 6.3 3.1 7.1
HIV infection              
Reports of new 
diagnoses of HIV 
infection through 
injecting drug use*
London Total number of reports: Injecting drug use n 54 58 67 71 66 68 103 78 61 51
Scotland Total number of reports: Injecting drug use n 17 17 12 13 11 20 16 7 16 13
Rest of UK Total number of reports: Injecting drug use n 48 67 49 85 70 100 85 95 104 85
UK
Total number of reports: Men who have sex 
with men also reporting injecting drug use
n 32 20 27 22 16 20 14 13 11 14
Prevalence among 
those having voluntary 
confidential HIV tests 
Scotland All injectors tested % 0.7 0.7 0.5 0.6 0.5 0.9 0.7 0.3 0.5 ††
Proportion HIV antibody 
positive~
England, 
Wales & 
Northern 
Ireland^
Current & former injectors % 0.8 1.0 0.9 1.2 1.4 1.6 1.3 1.1 1.6 1.5
First injected during the preceding 3 years % 0 0.4 0.2 0.8 0.6 1.3 0.8 1.0 1.3 0.7
Table 2: Summary of indicators of bacterial infections among injecting drug users in the United Kingdom
Table 3: Summary of indicators of risk and protective behaviours related to infections among injecting drug users  
in the United Kingdom
# Data on exposure is often incomplete or missing.
* Data on MRSA among IDUs is also available from HPA Staphylococcus Reference Unit (SRU). 
Between April 2003 and December 2008 SRU received 74 isolates from injecting drug users 
with sepsis due to a community-associated MRSA clone known as ST1-MRSA-IV which does 
not encode the Panton-Valentine Leukocidin (PVL) toxin. These cases have been identified 
from geographically distinct areas throughout England and Wales. No cases of this clone 
were identified among IDUs in 2009.
** Abscess, sore or open wound at an injection site in last year data. Year (numerator/
denominator): 2006 (668/2,072); 2007 (803/2,330); 2008 (654/2,138); 2009 (665/2,086). 
        
     
^ Includes Northern Ireland from 2002.
~ Unlinked Anonymous Monitoring survey of injectors in contact with drug services: www.
hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1202115519183
¶ Scottish drug misuse database: data are for financial years, for example, 2002 data 
relates to 2002/03 financial year. The data collection process for the Scottish Drug Misuse 
Database (SDMD) was revised in April 2006 and is not directly comparable.
§ Among individuals participating in a voluntary anonymous survey of injectors attending 
needle exchange services. 
Indicator Area Sub-Category  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Spore forming bacterial infections              
Reported cases of Wound Botulism UK Exposure injecting drug use n 5 4 19 15 41 28 22 3 4 22
Reported cases of Tetanus UK Exposure injecting drug use n 0 0 0 11 15 5 0 2 0 1
Group A streptococci (GAS) infections              
GAS isolate referrals to the HPA’s 
Streptococcus and Diphtheria Reference 
Unit
UK
Isolates with risk factor injecting 
drug use n 28 49 136 286 122 46 47 31 27 14
Proportion of all sterile site 
isolates % 3.6 6.7 15 22 11 4.5 3.9 3.4 2.2 0.9
Meticillin-resistant S. aureus (MRSA) 
infections
             
Mandatory enhanced surveillance of 
MRSA bacteraemias* 
England
Isolates with risk factor injecting 
drug use n - - - - - - 31 70 47 27
Proportion of all isolates, with 
exposure data, indicating 
injecting drug use#
% - - - - - - 3.4 3.6 3.3 3.1
Symptoms of a possible injection site 
bacterial infection
             
Having had an abscess, sore, or open 
wound at an injection site in last year: 
self-reports~
England, Wales & 
Northern Ireland^
Injecting drug users who 
had last injected during the 
preceding 12 months**
% - - - - - - 32 34 31 32
Indicator Area Sub-Category  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Risk Behaviours              
Passing on or receiving used needles or 
syringes in the last month: self reported~
England, Wales & 
Northern Ireland^
Current injectors % 31 33 34 29 28 28 23 23 19 19
Current injectors aged ≤ 24 % 31 36 44 37 36 38 29 26 22 27
Current injectors who first 
injected during the preceding 
3 years
% 24 28 33 28 27 28 21 25 17 17
Sharing of needles and syringes in past 
month: agency reports¶
Scotland Current injectors %
34 35 33 34 31 27 - - - -
- - - - - - 22 19 19 -
Sharing of any injecting equipment in 
past month: self reported~
England, Wales & 
Northern Ireland^ Current Injectors
% 60 59 60 55 55 53 48 47 41 37
Markers of health care utilization              
Ever used a needle and syringe 
programme: self reported~ 
England, Wales & 
Northern Ireland^ Current & former injectors
% 88 90 90 90 88 90 91 92 91 92
Ever had a voluntary confidential test for 
hepatitis C: self reported
England, Wales & 
Northern Ireland^~ Current & former injectors
% 49 54 58 63 67 71 75 74 77 81
Scotland§ Current & former injectors % - - - - - - - - 74
Proportion of those unaware that they 
have hepatitis C infection: self reported
England, Wales & 
Northern Ireland^~
Current & former injectors anti-
HCV positive
% 61 59 58 54 49 48 45 48 50 49
Scotland§
Current & former anti-HCV 
positive injectors
% - - - - - - - - 54
Hepatitis B vaccine uptake (receiving at 
least one dose of Hepatitis B vaccine): 
self reported
England, Wales & 
Northern Ireland^~
First injected during the 
preceding 3 years
% 26 28 36 42 51 46 61 54 62 68
Current & former injectors % 35 37 43 50 56 59 65 66 72 73
Scotland§
Injectors with less than 3 years 
since onset of injecting
% - - - - - - - - 51
Current & former injectors % - - - - - - - - 68
Ever had a voluntary confidential test for 
HIV: self reported~
England, Wales & 
Northern Ireland^~ Current & former injectors
% 52 55 58 62 63 66 69 68 72 75
Proportion of those unaware that they 
have HIV infection: self reported~
England, Wales & 
Northern Ireland^
Current & former injectors anti-
HIV positive
% 18 40 21 31 50 53 36 36 36 37
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England, Wales & 
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England, Wales & 
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% 49 54 58 63 67 71 75 74 77 81
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Proportion of those unaware that they 
have hepatitis C infection: self reported
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Current & former injectors anti-
HCV positive
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Current & former anti-HCV 
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DATA SOURCES: 
Reports of HIV infection
Voluntary confidential reports of new HIV 
diagnoses are received from laboratories and 
clinicians in England, Wales, and Northern 
Ireland by Centre for Infections (CfI). Scottish 
and paediatric data is collected locally and 
incorporated with data from England, Wales 
and Northern Ireland, at the end of each six 
month period to produce the current UK 
dataset. Surveillance began in 1982 with 
AIDS case reporting and expanded to include 
laboratory reporting of HIV diagnoses in 
1985. In England, Wales and Northern Ireland, 
clinician HIV reports were introduced in 2000 to 
supplement laboratory reporting, and the AIDS 
information is now collected on the clinician HIV 
report.  
HIV-infected individuals accessing HIV-
related care
A cross-sectional survey is carried out to identify 
all individuals with diagnosed HIV infection 
who attend for HIV-related care at NHS sites 
in England, Wales and Northern Ireland within 
a calendar year. Scottish and paediatric data 
is collected locally and incorporated annually 
to create a UK dataset. This survey has been 
repeated annually since 1995.
Laboratory reports of viral hepatitis and 
bacterial infection
Clinically significant infections diagnosed 
in England, Wales and Northern Ireland are 
routinely reported to CfI and held on a central 
system known as LabBase2. Most laboratories 
participate in the system, even if reporting is 
not mandatory. LabBase2 is, therefore, one of 
the most comprehensive sources of surveillance 
data, covering nearly all microbiologically-
confirmed infections. Data on infections caused 
by hepatitis B and C were all extracted from 
this reporting system. These reports contain 
demographic and risk information, although 
the risk factor information is not always 
provided. For acute hepatitis B laboratory 
surveillance data for England is combined with 
data collected from Health Protection Units. 
In Scotland, HPS collates data on all confirmed 
hepatitis C antibody tests from the main 
hepatitis C testing laboratories in Glasgow, 
Edinburgh, Dundee and Aberdeen.  
The Unlinked Anonymous Monitoring 
(UAM) survey of injecting drug users 
(IDUs)
The UAM survey of IDUs monitors HIV, hepatitis 
B and hepatitis C in injectors in contact with 
specialist services, such as needle exchanges, or 
on treatment programmes, such as methadone 
maintenance. Those who agree to participate 
provide either an oral fluid sample, or since 
2009 a dried blood spot sample, and complete 
a behavioural questionnaire. Detailed methods 
used for the survey have been published 
previouslyi,ii. The survey of IDUs has been 
ongoing since 1990 in England and Wales, and 
was extended to Northern Ireland in 2002.  
Further information about the UAM 
and comprehensive tables of data 
are available at: www.hpa.org.uk/
web/HPAweb&HPAwebStandard/
HPAweb_C/1202115519183 
Unlinked Anonymous Hepatitis C Testing 
of stored samples from IDUs in Scotland
Health Protection Scotland holds 
epidemiological information, including risk 
category (e.g. IDUs) and laboratory number, on 
all persons who have had a named HIV antibody 
test in Scotland since 1989. This allows the 
identification of residual blood from IDUs held 
at participating laboratories, which had been 
stored following their HIV antibody tests. Prior 
to testing for Hepatitis C antibodies, patient 
identifiers are irreversibly unlinked from their 
corresponding specimens, although selected 
non-identifying information (gender, age group, 
source laboratory/geographical area) is retained 
for epidemiological analysisiii.
i Unlinked Anonymous HIV Surveys Steering Group. Prevalence of HIV in the United Kingdom, Data to end of 1998. London: Department of Health, Public Health Laboratory 
Service, Institute of Child Health (London), Scottish Centre for Infection and Environmental Health; 1999.
ii Noone A, Durante AJ, Brady AR, Majid F, Swan AV, Parry JV, et al.  HIV infection in injecting drug users attending centres in England and Wales, 1990-1991.  AIDS 1993; 7: 1501-7.
iii Hutchinson SJ, McIntyre PG, Molyneaux P, Cameron S, Burns S, Taylor A, Goldberg DJ. Prevalence of hepatitis C among injectors in Scotland 1989-2000: declining trends 
among young injectors halt in the late 1990s. Epidemiol & Infect 2002; 128: 473-7.
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Needle Exchange Surveillance Initiative 
(NESI)
The aim of NESI is to measure and monitor 
the prevalence of hepatitis C and injecting 
risk behaviours among injecting drug users 
in Scotland. The initiative is funded by the 
Scottish Government as part of the Scottish 
Hepatitis C Action Plan. A cross-sectional 
voluntary anonymous survey approach was 
used to recruit and interview injectors during 
June 2008 to June 2009. Trained interviewers 
recruited participants from selected needle 
exchange services and pharmacies that provide 
injecting equipment. Clients attending these 
services were invited to take part if they had 
ever injected drugs. After providing informed 
consent, participants completed a short 
interviewer-administered questionnaire and 
provided a voluntary blood spot sample for 
anonymous hepatitis C testingiv.
Reference laboratory submissions
The key source of data on S. aureus infections 
in IDUs is through referral of isolates to the 
Staphylococcus Reference Unit (part of CfI) for 
reference microbiology. 
Isolate referrals to the national reference 
laboratory, the Respiratory and Systemic 
Infection Laboratory (part of CfI), are one of the 
primary sources of Group A Streptococcal (GAS) 
infection reports.
Data on clostridial infections is also available 
from reference microbiology work. For botulism, 
this is carried out by Foodborne Pathogens 
Reference Unit and for tetanus by Respiratory 
and Systemic Infection Laboratory. For the other 
clostridia, this is undertaken by the Anaerobe 
Reference Laboratory, NPHS Microbiology 
Cardiff.
Notifications of infectious diseases
Clinicians throughout the UK are required by 
law to report a number of defined conditions 
to their local communicable disease specialist. 
Tetanus and hepatitis A, B and C are among 
these notifiable diseases.
Mandatory enhanced surveillance of 
MRSA bacteraemia
English NHS Acute Trusts have been required 
to report episodes of MRSA bacteraemia since 
October 2005. In addition to mandatory 
information regarding each bacteraemia case, 
the system also collects further information 
concerning the consultant specialty, care details 
at the time the blood sample was taken, and 
risk factors associated with MRSA bacteraemia. 
Risk factor information is voluntarily completed. 
Enhanced surveillance of tetanus 
Enhanced surveillance of tetanus is carried out 
by the CfI Immunisation, Hepatitis and Blood 
Safety Department. Reports are followed up 
with a surveillance questionnaire. 
www.hpa.org.uk/Topics/InfectiousDiseases/
InfectionsAZ/Tetanus/Surveillance
Surveillance of wound botulism 
Surveillance of wound botulism among IDUs is 
carried out by the CfI HIV & STI Department, 
with Foodborne Pathogens Reference Unit. 
Reports are followed up with a surveillance 
questionnaire. 
www.hpa.org.uk/Topics/InfectiousDiseases/
InfectionsAZ/Botulism/GeneralInformation/
botubotu020Woundbotulismcasesininjecting
drugusers                      
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iv University of the West of Scotland, Health Protection Scotland and West of Scotland Specialist Virology Centre. The Needle Exchange Surveillance Initiative (NESI): Prevalence 
of HCV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009. University of the West of Scotland, April 2010.
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